Home › Burkitt Lymphoma › Wisconsin
Burkitt Lymphoma clinical trials in Wisconsin
17 studies for Burkitt Lymphoma are looking for participants at sites in Wisconsin.
Cities in Wisconsin
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- and 1 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693Blinatumomab Consolidation in Real World
- Medical College of Wisconsin, Milwaukee
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- Marshfield Medical Center-Marshfield, Marshfield
- Froedtert Menomonee Falls Hospital, Menomonee Falls
- and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- and 1 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Milwaukee
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Froedtert & the Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
- Children's Wisconsin, Milwaukee
Recruiting
Ages 0 to 25 · All sexes · Updated May 13, 2026 · NCT05794880Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Nov 10, 2025 · NCT03375619Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Wisconsin Carbone Cancer Center, Madison
RecruitingPhase 1/2
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 17, 2021 · NCT04746209From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.